Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (NASDAQ: FLGT) regularly issues news and updates that reflect its dual focus on laboratory services and oncology therapeutic development. Company press releases cover topics such as quarterly and annual financial results, clinical trial progress for its cancer drug candidates, regulatory milestones for its genomic testing platforms, and strategic transactions in the laboratory and pathology space. Because Fulgent describes itself as a technology-based company with ambitions in precision medicine, its news flow often highlights both operational performance and advances in its technology and therapeutic pipelines.
Investors following FLGT news can expect detailed earnings releases that discuss revenue, core revenue, GAAP and non-GAAP results, gross margins, and adjusted EBITDA, along with commentary from management on business trends in the laboratory services and therapeutic development segments. The company also announces the timing of upcoming earnings calls and investor conference presentations through news releases, providing context for when management will discuss the business with the investment community.
Beyond financial reporting, Fulgent’s news includes updates on its oncology programs, such as preliminary clinical data from trials of FID-007 in recurrent or metastatic head and neck squamous cell carcinoma. The company also reports on regulatory achievements, including CE certification in the European Union for its FulgentExome and Fulgent Pipeline Manager (PLM) germline next-generation sequencing system. In addition, Fulgent uses press releases to announce strategic moves in laboratory and pathology services, such as its agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx.
This FLGT news page aggregates these types of announcements so readers can review financial disclosures, clinical development updates, technology milestones, and transaction-related news in one place. For those tracking Fulgent’s progress toward its stated goal of becoming a fully integrated precision medicine company, the news feed provides an ongoing view of how the company reports its operational and strategic developments.
Fulgent Genetics (NASDAQ: FLGT) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. The company's executives, including Chairman and CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, will host a presentation at 8:40 a.m. ET.
A live webcast of the event will be accessible via the Investor Relations section of Fulgent Genetics' website.
Fulgent Genetics, Inc. (NASDAQ: FLGT) reported record fourth quarter 2020 results with revenue of $295.0 million, a remarkable 3,400% increase year-over-year. The company achieved GAAP income of $166.3 million or $6.16 per share. Full-year revenue was $421.7 million, up 1,200% from 2019. Looking ahead to 2021, Fulgent anticipates overall revenue of approximately $800.0 million, reflecting a 90% growth. Non-COVID revenue grew 43% in Q4, and the company continues to expand its testing capabilities and customer base.
Fulgent Genetics (NASDAQ: FLGT) announced it will release its Q4 and full-year 2020 financial results on March 4, 2021, after market close. The company's CEO Ming Hsieh and other executives will host a conference call to discuss the results at 4:30 PM ET (1:30 PM PT). Investors can access the call via a live audio webcast or by dialing (855) 321-9535 with conference ID 7669989. A replay will be available until March 11, 2021.
Fulgent's technology platform offers comprehensive testing solutions, including SARS-CoV-2 detection tests, with Emergency Use Authorization from the FDA.
Fulgent Genetics (NASDAQ: FLGT) has announced that its CFO, Paul Kim, and CCO, Brandon Perthuis, will present virtually at the H.C. Wainwright BIOCONNECT 2021 Conference from January 11-14, 2021. A webcast of the presentation will be available at 6:00 a.m. ET on January 11 on the company’s Investor Relations page and accessible for 90 days. Fulgent Genetics specializes in comprehensive testing solutions and has launched various tests for SARS-CoV-2, receiving Emergency Use Authorization from the FDA for its RT-PCR tests.
Fulgent Genetics (Nasdaq: FLGT) has been awarded a contract to continue providing COVID-19 testing for NYC public schools through the end of the 2021 school year. The partnership, established following a competitive selection process, will deploy Fulgent's FDA EUA-approved RT-PCR tests, ensuring results within 24 hours. The testing will utilize a less invasive nasal swab method for students and staff. This extension underscores Fulgent's proven capabilities, with significant positive feedback on its testing process, which is highly scalable and efficient.
Fulgent Genetics (NASDAQ: FLGT) announced participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The company’s top executives, including CEO Ming Hsieh and CFO Paul Kim, will engage in a pre-recorded fireside chat, which will be accessible via their Investor Relations webpage for 90 days post-conference. Fulgent Genetics specializes in comprehensive testing solutions, notably in genetic testing and COVID-19 detection, emphasizing high accuracy, competitive turnaround times, and customizable testing options through their advanced technology platform.
Fulgent Genetics (NASDAQ: FLGT) has revised its 2020 revenue guidance to at least $300 million, a significant increase of 28% from the prior estimate of $235 million. This marks over 800% growth year-over-year, driven by rising demand for COVID-19 testing as cases surge across the U.S. The company reports a testing capacity exceeding 60,000 tests per day, positioning it to meet growing market needs effectively. Fulgent's advanced technology platform supports a broad test menu, including RT-PCR tests for SARS-CoV-2, receiving Emergency Use Authorization from the FDA.
Fulgent Genetics (NASDAQ:FLGT) has partnered with the Los Angeles Network for Enhanced Services (LANES) and the LA County Department of Health Services to expedite the sharing of COVID-19 test results from nearly 20 local testing sites. This initiative aims to improve patient care through rapid access to test data, which is essential as COVID-19 cases surge in LA County. Since May 25, Fulgent has been conducting thousands of tests daily, facilitating electronic sharing of results to inform healthcare providers. The partnership enhances healthcare response by integrating test results into electronic health records within 24 hours.
Fulgent Genetics (NASDAQ: FLGT) announced that CFO Paul Kim and CCO Brandon Perthuis will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 11, 2020, at 3:30 p.m. ET. A live webcast of the presentation will be accessible on the company’s Investor Relations website.
The company offers comprehensive testing solutions, including its proprietary technology platform for genetic testing and COVID-19 detection, supported by Emergency Use Authorization from the FDA for its RT-PCR tests and at-home testing services.
Fulgent Genetics (FLGT) reported a record revenue of $101.7 million for Q3 2020, up 883% year-over-year. The company delivered approximately 1.04 million billable tests, marking a growth of 4,800%. Gross margin improved by 19 percentage points sequentially, and non-COVID revenue increased by 57% from Q2. GAAP earnings reached $46.6 million or $1.98 per share, with non-GAAP earnings of $49.0 million or $2.08 per share. The full-year revenue guidance has been raised to $235 million.